Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 195

1.

Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease.

Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B.

Hepatol Commun. 2017 Sep;1(7):609-622. doi: 10.1002/hep4.1068. Epub 2017 Jul 17.

2.

Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE; NASH Clinical Research Network.

Hepatology. 2017 Jan;65(1):65-77. doi: 10.1002/hep.28776. Epub 2016 Oct 12.

3.

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

Bajaj JS, Frederick RT, Bass NM, Ghabril M, Coyne K, Margolis MK, Santoro M, Coakley DF, Mokhtarani M, Jurek M, Scharschmidt BF.

Metab Brain Dis. 2016 Oct;31(5):1081-93. doi: 10.1007/s11011-016-9851-9. Epub 2016 Jun 9.

PMID:
27278222
4.

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1390-7.e2. doi: 10.1016/j.cgh.2013.12.021. Epub 2013 Dec 21.

5.

Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis.

Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

Liver Int. 2014 Sep;34(8):1250-8. doi: 10.1111/liv.12379. Epub 2013 Nov 24.

6.

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF; HALT-HE Study Group.

Hepatology. 2014 Mar;59(3):1073-83. doi: 10.1002/hep.26611.

7.

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Oct;56(4):1311-8. doi: 10.1002/hep.25805. Epub 2012 Aug 21.

8.

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Sep;56(3):943-51. doi: 10.1002/hep.25772. Epub 2012 Jul 26.

9.

SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome.

Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stančáková A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV Jr, Kahn CR, Verdin E.

Mol Cell. 2011 Oct 21;44(2):177-90. doi: 10.1016/j.molcel.2011.07.019.

10.

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.

11.

Centrizonal arteries and microvessels in nonalcoholic steatohepatitis.

Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD.

Am J Surg Pathol. 2011 Sep;35(9):1400-4. doi: 10.1097/PAS.0b013e3182254283.

12.

Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.

Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA.

Liver Transpl. 2011 Dec;17(12):1380-6. doi: 10.1002/lt.22389.

13.

Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.

Yong CM, Sharma M, Ochoa V, Abnousi F, Roberts J, Bass NM, Niemann CU, Shiboski S, Prasad M, Tavakol M, Ports TA, Gregoratos G, Yeghiazarians Y, Boyle AJ.

Liver Transpl. 2010 Nov;16(11):1242-8. doi: 10.1002/lt.22152.

14.

Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors.

Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, Josephson SA.

Clin Neurol Neurosurg. 2010 Dec;112(10):886-91. doi: 10.1016/j.clineuro.2010.07.023. Epub 2010 Aug 25.

PMID:
20800343
15.

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network.

Hepatology. 2010 Sep;52(3):913-24. doi: 10.1002/hep.23784.

16.

The treatment of hepatic encephalopathy in the cirrhotic patient.

Sanyal AJ, Mullen KD, Bass NM.

Gastroenterol Hepatol (N Y). 2010 Apr;6(4 Suppl 8):1-12.

17.

Emergent orthotopic liver transplantation for hemorrhage from a giant cavernous hepatic hemangioma: case report and review.

Vagefi PA, Klein I, Gelb B, Hameed B, Moff SL, Simko JP, Fix OK, Eilers H, Feiner JR, Ascher NL, Freise CE, Bass NM.

J Gastrointest Surg. 2011 Jan;15(1):209-14. doi: 10.1007/s11605-010-1248-1. Epub 2010 Jun 12.

18.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.

N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.

19.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

20.

Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffic.

Bass NM.

Hepatology. 2010 Jan;51(1):4-7. doi: 10.1002/hep.23458. No abstract available.

PMID:
20034031

Supplemental Content

Support Center